BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sleutjes JAM, van Lennep JER, van der Woude CJ, de Vries AC. Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therap Adv Gastroenterol 2021;14:17562848211032126. [PMID: 34377149 DOI: 10.1177/17562848211032126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Kochar BD, Cheng D, Cai T, Ananthakrishnan AN. Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2022;67:5206-12. [PMID: 35113275 DOI: 10.1007/s10620-022-07404-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Rueda-Gotor J, Ferraz-Amaro I, Genre F, González Mazón I, Corrales A, Portilla V, Llorca J, Agudo-Bilbao M, Aurrecoechea E, Expósito R, Hernández-Hernández V, Quevedo-Abeledo JC, Rodríguez-Lozano C, Lopez-Medina C, Ladehesa-Pineda ML, Castañeda S, Vicente EF, Fernández-Carballido C, Martínez-Vidal MP, Castro-Corredor D, Anino-Fernández J, Peiteado D, Plasencia-Rodríguez C, Vivar MLG, Galíndez-Agirregoikoa E, Perez EM, Fernández Díaz C, Blanco R, González-Gay MÁ. Cardiovascular and disease-related features associated with extra-articular manifestations in axial spondyloarthritis. A multicenter study of 888 patients. Semin Arthritis Rheum 2022;57:152096. [PMID: 36150319 DOI: 10.1016/j.semarthrit.2022.152096] [Reference Citation Analysis]
3 Sleutjes JAM, Roeters van Lennep JE, de Vries AC. Spotlight on Cardiovascular Risk Assessment in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2022;67:4326-9. [PMID: 35304651 DOI: 10.1007/s10620-022-07449-0] [Reference Citation Analysis]
4 Kountouras J, Papaefthymiou A, Polyzos SA, Liatsos C, Tzitiridou-Chatzopoulou M, Chatzopoulos D, Vardaka E, Gialamprinou D, Kotronis G, Thavayogarajah T, Doulberis M. Adverse Outcomes of E-cigarette in Inflammatory Bowel Disease. Dig Dis Sci 2022. [PMID: 35930122 DOI: 10.1007/s10620-022-07642-1] [Reference Citation Analysis]
5 Jucan AE, Gavrilescu O, Dranga M, Popa IV, Mihai BM, Prelipcean CC, Mihai C. Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention. Life (Basel) 2022;12:1113. [PMID: 35892915 DOI: 10.3390/life12081113] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]